<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1870-7203</journal-id>
<journal-title><![CDATA[Acta médica Grupo Ángeles]]></journal-title>
<abbrev-journal-title><![CDATA[Acta méd. Grupo Ángeles]]></abbrev-journal-title>
<issn>1870-7203</issn>
<publisher>
<publisher-name><![CDATA[Grupo Ángeles, Servicios de Salud]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1870-72032020000100106</article-id>
<article-id pub-id-type="doi">10.35366/92017</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Epilepsia tumoral]]></article-title>
<article-title xml:lang="en"><![CDATA[Tumoral epilepsy]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cano Aguilar]]></surname>
<given-names><![CDATA[Luis Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Díaz Alba]]></surname>
<given-names><![CDATA[Alexandra]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cacho Díaz]]></surname>
<given-names><![CDATA[Bernardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Durán Peña]]></surname>
<given-names><![CDATA[Alberto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad La Salle Facultad Mexicana de Medicina ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Tecnológico de Estudios Superiores de Monterrey  ]]></institution>
<addr-line><![CDATA[Guadalajara Jalisco]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Nacional de Cancerología  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Universidad de Pierre et Marie Curie Hospital de la Pitié-Salpêtrière ]]></institution>
<addr-line><![CDATA[París ]]></addr-line>
<country>Francia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2020</year>
</pub-date>
<volume>18</volume>
<numero>1</numero>
<fpage>106</fpage>
<lpage>110</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1870-72032020000100106&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1870-72032020000100106&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1870-72032020000100106&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: La epilepsia tumoral es un desorden neurodegenerativo que forma parte del 6% de las epilepsias diagnosticadas en la actualidad. Cada vez cobra más importancia debido a la morbilidad de los pacientes con tumores cerebrales primarios, y se presenta más frecuentemente en pacientes con metástasis cerebrales. Este trastorno se describe como una localización supratentorial en la capa supragranular de la neocorteza peritumoral. Las moléculas proepileptógenas, involucradas en la fisiopatología, son el glutamato, el ácido gamma-aminobutírico (GABA), el potasio, el fibrinógeno y la albúmina. Las alteraciones del sistema nervioso central (SNC) se explican por medio de dos teorías: la teoría epileptocéntrica y la teoría tumorocéntrica. La importancia de la epilepsia tumoral reside en que se considera como un signo de presentación en estirpes tumorales específicas (gangliogliomas y oligodendrogliomas), y en que es un marcador objetivo de progresión tumoral. El electroencefalograma y la resonancia magnética nuclear son las dos herramientas de diagnóstico esenciales. Su manejo se divide en tratamiento farmacológico y quirúrgico, considerando la estirpe tumoral, la expresión temporal de las crisis, la respuesta a tratamiento médico, y el estado de salud del paciente y su pronóstico a corto y largo plazo, lo que impacta directamente en la morbimortalidad de los pacientes con tumores en el sistema nervioso central.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: Tumoral epilepsy is a neurodegenerative disorder that represents 6% of all currently diagnosed epilepsies. This disorder is frequently described in a supratentorial location in the supragranular layer of the peritumoral neocortex. The proepileptogenic molecules involved in the pathophysiology are glutamate, gamma aminobutyric acid (GABA), potassium, fibrinogen and albumin, whose alterations in the central nervous system (CNS) are explained by two theories: epileptocentric and the tumorocentric theory. The importance of tumoral epilepsy relies in being considered a sign of presentation of specific tumoral lines (ganglioglioma, oligodendroglioma) and acting as an objective marker of tumoral progression. The electroencephalogram and the nuclear magnetic resonance are the two essential diagnostic tools. The management of tumoral epilepsy is based on pharmacological and surgical treatment, taking into consideration the tumor excision, the timing of the seizures, response to treatment, the patient&#8217;s prognosis, directly impacting on the morbidity and mortality of patients with CNS tumors.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Epilepsia]]></kwd>
<kwd lng="es"><![CDATA[convulsiones]]></kwd>
<kwd lng="es"><![CDATA[enfermedades neurodegenerativas]]></kwd>
<kwd lng="es"><![CDATA[neoplasia]]></kwd>
<kwd lng="en"><![CDATA[Epilepsy]]></kwd>
<kwd lng="en"><![CDATA[seizures]]></kwd>
<kwd lng="en"><![CDATA[neurodegenerative diseases]]></kwd>
<kwd lng="en"><![CDATA[neoplasms]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lhatoo]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Moghimi]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Schuele]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tumor-related epilepsy and epilepsy surgery]]></article-title>
<source><![CDATA[Epilepsia]]></source>
<year>2013</year>
<volume>54</volume>
<page-range>1-4</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kerkhof]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vecht]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Seizure characteristics and prognostic factors of gliomas]]></article-title>
<source><![CDATA[Epilepsia]]></source>
<year>2013</year>
<volume>54</volume>
<page-range>12-7</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pallud]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Capelle]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Huberfeld]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tumoral epileptogenicity: how does it happen?]]></article-title>
<source><![CDATA[Epilepsia]]></source>
<year>2013</year>
<volume>54</volume>
<page-range>30-4</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vecht]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kerkhof]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Duran-Pena]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Seizure prognosis in brain tumors: new insights and evidence-based management]]></article-title>
<source><![CDATA[Oncologist]]></source>
<year>2014</year>
<volume>19</volume>
<page-range>751-9</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rudà]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bello]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Duffau]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Soffietti]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments]]></article-title>
<source><![CDATA[Neuro Oncol]]></source>
<year>2012</year>
<volume>4</volume>
<page-range>55-64</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perucca]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Optimizing antiepileptic drug treatment in tumoral epilepsy]]></article-title>
<source><![CDATA[Epilepsia]]></source>
<year>2013</year>
<volume>54</volume>
<page-range>97-104</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Koekkoek]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Kerkhof]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dirven]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Heimans]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Reijneveld]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Taphoorn]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Seizure outcome after radiotherapy and chemotherapy in low-grade glioma patients: a systematic review]]></article-title>
<source><![CDATA[Neuro Oncol]]></source>
<year>2015</year>
<volume>17</volume>
<page-range>924-34</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cacho-Díaz]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[San-Juan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Salmeron]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Boyzo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lorenzana-Mendoza]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Choice of antiepileptic drugs affects the outcome in cancer patients with seizures]]></article-title>
<source><![CDATA[Clin Transl Oncol]]></source>
<year>2018</year>
<volume>20</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1571-6</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kerkhof]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dielemans]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[van Breemen]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Zwinkles]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Walchenbach]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Taphoorn]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Vecht]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme]]></article-title>
<source><![CDATA[Acta Neurol Scand]]></source>
<year>2016</year>
<volume>133</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>4-16</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
